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Invasive candidiasis is associated with high mortality rates, ranging from 35% to 60%, in the
range reported for septic shock. The epidemiology and pathogenesis of invasive candidi-
asis differ according to the patient’s immune status; the majority of cases in immuno-
compromised hosts are candidaemia, whereas non-candidaemic systemic candidiasis
accounts for the majority of cases in critically ill patients. In contrast to candidaemia,
non-candidaemic systemic candidiasis is difficult to prove, especially in critically ill pa-
tients. Up to 80% of these patients are colonized, but only 5e30% develop invasive
infection. The differentiation of colonization and proven infection is challenging, and
evolution from the former to the latter requires seven to 10 days. This continuum from
colonization of mucosal surfaces to local invasion and then invasive infection makes it
difficult to identify those critically ill patients likely to benefit most from antifungal
prophylaxis or early empirical antifungal treatment. Early empirical treatment of non-
candidaemic systemic candidiasis currently relies on the positive predictive value of risk
assessment strategies, such as the colonization index, candida score, and predictive rules
based on combinations of risk factors such as candida colonization, broad-spectrum an-
tibiotics, and abdominal surgery. Although guidelines recently scored these strategies as
being supported by limited evidence, they are widely used at bedside and have substan-
tially decreased the incidence of invasive candidiasis.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the Healthcare Infection So-
ciety. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Candida spp. colonization develops in up to 80% of critically
ill patients staying more than one week in intensive care,
whereas invasive candidiasis is documented in only 5e10% of
them.15 Early diagnosis of invasive candidiasis is difficult; it isent of Intensive Care
audois (CHUV), Rue du
el.: þ41 21 314 2923;
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rg/licenses/by-nc-nd/3.0/).generally late in the course of the infection before microbio-
logical evidence is found.68 This may delay appropriate anti-
fungal treatment and may be in part responsible for its high
crude and attributable mortality rates, comparable to those
reported for septic shock.911
Antifungal prophylaxis and early empirical treatment of
severe candidiasis has improved survival, but may result in
overuse of antifungal agents if indiscriminately prescribed to
all patients colonized by Candida spp.1214 Indeed, extensive
use of antifungals has promoted a shift to Candida spp. with
reduced susceptibility.15,16 Recent guidelines resulting from
expert consensus provided no high-level recommendations
about antifungal prophylaxis and empirical antifungalealthcare Infection Society. This is an open access article under the CC
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laxis and empirical treatment currently rely on the identifica-
tion of patients with a high documented risk and on the positive
predictive value of risk assessment strategies, such as the
colonization index, candida score, and predictive rules based
on combinations of risk factors.1921
Identification of patients who could benefit from antifungal
prophylaxis and empirical treatment may, however, be
improved by taking into account some pathophysiological
specificities of invasive candidiasis.22,23
Epidemiology and pathophysiology of invasive
candidiasis
Invasive candidiasis includes two closely related and often
confused conditions: candidaemia and non-candidaemic sys-
temic candidiasis. Candidaemia requires the growth of Candida
spp. from the blood of a patient with temporally related signs
of infection. In the intensive care unit (ICU), candidaemia
ranges from five to 10 cases per 1000 admissions or three to 15
episodes per 10,000 patient days (five to 10 times the incidence
on general hospital wards).6,24,25 Non-candidaemic systemic
candidiasis corresponds to candida invasion, established by
culture or histology, of normally sterile sites. Accordingly, the
epidemiology of non-candidaemic systemic candidiasis is hard
to determine. In a worldwide prevalence study performed in
1265 ICUs in May 2007, candida infection was reported in 17%
(841/4947) of patients with microbiologically documented
infection, but candidaemia was documented in only 99
cases.2,5 Invasive candidiasis is characterized by specific
physiopathological characteristics (Table I).
Exogenous nosocomial transmission of candida has been
reported, but studies using genotyping of candida strains
showed that endogenous colonization is responsible for the
large majority of severe candidiasis.2628 This explains why
invasive candidiasis is characterized by seven- to 10-day delay
between exposure to risk factors and development of
infection.2931 The pathophysiology of invasive candidiasis
differs markedly between immunocompromised and critically
ill patients.22,23 In immunocompromised patients, prolongedTable I
Pathophysiological characteristics of invasive candidiasis according to
Pathophysiological characteristics Immuno
Immunity
Neutrophils
Macrophages
T-cells
Ulcerations of mucosal surfaces
Oropharyngeal
Upper digestive tract
Lower digestive tract
Typhlitis
Digestive surgery
Antibiotic exposure
Organ failure
Candida colonization
Invasive candidiasis
Candidaemia
Non-candidaemic systemic candidiasisneutropenia or functional impairment (transplanted patients),
with eventual mucosal injuries resulting from chemotherapy
combined with the selective pressure of frequent and repeti-
tive exposure to antibacterial agents, results in high preva-
lence of invasive candidiasis with a large proportion of
bloodstream infections.
In critically ill patients, other factors explain the high
prevalence of invasive candidiasis. Prolonged support of failing
organs combined with the selective pressure of broad-
spectrum antibiotics constitutes key risk factors for invasive
candidiasis in non-surgical critically ill patients.1,5 These fac-
tors may explain progressive colonization in a high proportion
of patients after prolonged stay in the ICU. They may also
explain a higher proportion of catheter-related infections in
the absence of severe immune impairment.6,3234
Additional factors play a specific role in patients after
abdominal surgery.35 Opening or perforation of the bowel re-
sults in contamination of the peritoneum by digestive flora.
Surgical cleaning of the abdominal cavity combined with anti-
biotics is sufficient to allow full recovery in most cases, where
the identification of Candida spp. has no clinical signifi-
cance.22,36 Alternatively, colonization may progress to invasive
candidiasis in recurrent peritonitis following anastomotic
leakage.3740 These factors may explain why candidaemia is
not documented in most cases of invasive candidiasis in surgical
patients until late in the disease, if at all.40
The interval between exposure to risk factors and devel-
opment of invasive disease opens a window of about one week
for a structured evaluation to identify patients who may truly
benefit from antifungal prophylaxis or early empirical anti-
fungal treatment according to the underlying condition and
immune status.7,19,41
Antifungal prophylaxis
The bad prognosis of invasive candidiasis has stimulated the
use of systematic antifungal prophylaxis in most immunocom-
promised patients over the past three decades.42 This is
considered to be responsible for the evolution of the epidem-
iology of candida infections, characterized by breakthroughimmune status
compromised patients Critically ill patients
Decreased Increased
Decreased Increased
Decreased Normal
þþ to þþþ 0 to þ
þþ to þþþ 0 to þ
þþ to þþþ 0 to þ
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0 þ þ to þþþ
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resistant to the antifungal agent used for prophylaxis.15,4345
The success of antifungal prophylaxis in bone marrow and
solid organ transplant recipients has stimulated investigators
to promote it in critically ill patients. Clinical results, however,
should be interpreted with caution. Studies involving unse-
lected critically ill patients at low risk (<10%) of invasive
candidiasis failed to demonstrate any benefit of antifungal
prophylaxis [number needed to treat (NNT): 20e50].46,47 To
avoid overuse of antifungals, we and others have emphasized
that prophylaxis should target only critically ill patients in
whom it has been shown useful.19,38,39,48,49 In these highly
selected populations, representing only 1e3% of all ICU ad-
missions, the NNT ranged from three to 10. This concept has
been acknowledged and validated in guidelines for the man-
agement of invasive candidiasis in immunocompetent
hosts.17,18 Based on the available evidence, they state that
institutions in which high rates of invasive candidiasis in adult
ICU patients persist despite standard infection-control pro-
cedures should consider fluconazole prophylaxis only for highly
selected ICU patients.1719 Two small prospective studies,
including one placebo-controlled, suggested that antifungal
prophylaxis in patients presenting with anastomotic leakage
after abdominal surgery may prevent the development of
invasive candidiasis.18,38,39
Antifungal prophylaxis, however, should not be given to all
ICU patients. In the absence of routinely available biomarkers
to guide early empirical antifungal treatment, several risk-
based strategies have been proposed to identify patients
likely to benefit most.Risk-based strategies to guide empirical
antifungal treatment
Non-candidaemic systemic candidiasis represents the ma-
jority of invasive candidiasis cases occurring in critically ill
patients, and early empirical antifungal treatment avoids
delayed treatment of documented infection, which signifi-
cantly worsens the outcome.12,13,50 Unfortunately, the defini-
tion of microbiologically demonstrated infection is restrictive
and cannot be used to guide antifungal initiation in clinical
practice.1921,23,34 Thus, early empirical treatment currently
relies on the positive predictive value of risk assessment
strategies, such as (1) colonization index, (2) candida score,
and (3) predictive rules.19,21,23,30,5154 These risk-based strat-
egies share common characteristics: first, they are based on
combinations of several risk factors, such as candida coloni-
zation, previous use of broad-spectrum antibiotics, and previ-
ous abdominal surgery; second, their positive predictive values
(PPVs) are used for the early prediction of invasive candidiasis;
third, their negative predictive values (NPVs) are much higher
than their PPVs, for which they were developed (Table II).Colonization index
The documentation of increasing amounts of Candida spp. in
semiquantitative cultures from multiple sites predicts the
subsequent development of invasive candidiasis.1 The evalua-
tion of colonization dynamics by periodic colonization index
calculation accurately predicted the development of invasive
candidiasis.33,35,36 In a prospective cohort study of critically illsurgical patients, Pittet et al. assessed the degree of coloni-
zation by daily colonization index defined as the ratio of the
number of distinct non-blood body sites colonized by Candida
spp. to the total number of body sites cultured.30 Only strains
of Candida spp. with the same genetic identity were consid-
ered.29 Eleven of 29 heavily colonized patients developed
invasive candidiasis, which was independently predicted by the
degree of colonization. Average candida colonization indices in
colonized and infected patients were 0.47 and 0.7, respec-
tively (P < 0.01). Furthermore, a colonization index threshold
of 0.5 enabled the identification of all infected patients on
average six days before the diagnosis of infection.
A recent review on candida colonization index showed that
it has been successfully used to characterize colonization dy-
namics, to assess the significance of candiduria, and to eval-
uate the impact of antifungal prophylaxis.23 Despite limited
bedside practicability, we concluded that the colonization in-
dex remains an important surrogate of the dynamics of colo-
nization, which increases early in patients who develop
invasive candidiasis.
Candida score
The candida score is a development of the colonization in-
dex.51 In a prospective cohort study of 1699 patients staying
more than seven days in the ICU, Leon et al. found that surgery
[odds ratio (OR): 2.71; 95% confidence interval (CI):
1.45e5.06], multifocal colonization (OR: 3.04; 95% CI:
1.45e6.39), total parenteral nutrition (OR: 2.48; 95% CI:
1.16e5.31), and severe sepsis (OR: 7.68; 95% CI: 4.14e14.22)
predicted invasive candidiasis. When one point was attributed
to each risk factor (but two for severe sepsis) and a cut-off
value of 2.5 was used, the candida score showed 81% sensi-
tivity and 74% specificity. We and others showed that the ac-
curacy of a candida score 3 was greater than that of a
colonization index 0.5.40,58,59 The usefulness of this score in
ruling out the risk of invasive candidiasis has also been
demonstrated.58 In a multicentre cohort of 1007 patients
staying more than seven days in ICU, only 13/565 (2.3%) pa-
tients with candida scores <3 developed candidiasis, corre-
sponding to an NPV of 98%. However, the usefulness of the
candida score to guide empirical antifungal treatment has not
been tested in prospective clinical studies.
Predictive rules
Up to five risk factors associated with invasive candidiasis in
retrospective analyses of cohorts of critically ill patients were
combined to develop predictive rules for the early identifica-
tion of critically ill patients at high risk of developing invasive
candidiasis.21 Despite progressive improvement in the accuracy
of these rules, three industry-sponsored studies failed to
demonstrate their clinical usefulness in guiding the early
initiation of empirical antifungal treatment in critically ill pa-
tients. A predictive rule was used in a multicentre, random-
ized, double-blind, placebo-controlled trial comparing
caspofungin with placebo as antifungal prophylaxis in 222
critically ill patients with ICU stays of three or more days who
were ventilated, received antibiotics, had a central line cath-
eter, and had one of the following additional risk factors:
parenteral nutrition, dialysis, surgery, pancreatitis, systemic
steroids, or other immunosuppressants.60 The incidence of
Table II
Accuracy of risk prediction models for invasive candidiasis in critically ill patientsa
Reference Population, IC Risk-based prediction model Accuracy of
prediction
Pittet et al.30 29 patients heavily colonized with
Candida spp. (11 developed IC)
Colonization index: threshold ¼ 0.5 PPV ¼ 66%
NPV ¼ 100%
Paphitou et al.52 327 ICU patients staying 4 days [23
(11%) developed IC]
Predictive rule e one of the following:
diabetes, total parenteral nutrition, prior
ICU stay, new onset haemodialysis, on
broad-spectrum antibiotics
Captured 52% of IC
Sensitivity ¼ 83%
Specificity ¼ 50%
PPV ¼ 11%
NPV ¼ 98%
Leon et al.51 1669 patients [97 (6%) with IC]
staying 7 days in 73 mixed Spanish
ICUs
Candida score e to predict IC, sum of:
severe sepsis (2 points), surgery (1), total
parenteral nutrition (1), multifocal
candida colonization (1). Threshold ¼ 2.5
points.
Captured 81% of IC
Sensitivity ¼ 81%
Specificity ¼ 74%
PPV ¼ 16%
NPV ¼ 98%
Ostrosky-Zeichner et al.53 2890 patients [88 (3%) with proven or
probable IC] staying 4 days in nine
US/Brazilian ICUs
Predictive rule e both systemic antibiotics
and central venous catheter (day 1e3 of
ICU stay); plus two of total parenteral
nutrition (day 1e3 of ICU stay), dialysis
(day 1e3 of ICU stay), major surgery (day
e7 to 0 of ICU stay), pancreatitis (day e7
to 0 of ICU stay), steroids (day e7 to 3 of
ICU stay), other immunosuppressive agents
(day e7 to 0 of ICU stay)
Captured 34% of IC
Sensitivity ¼ 34%
Specificity ¼ 90%
PPV ¼ 10%
NPV ¼ 97%
Ostrosky-Zeichner et al.54 649 patients from mixed ICUs [12
(1.8%) developed IC]. Risk factors as
above combined with the presence
of Candida in specimens routinely
collected
Predictive rule: all of: mechanical
ventilation, broad-spectrum antibiotics
and central venous catheter (day 1e3 of
ICU stay); plus one of: total parenteral
nutrition (day 1e3 of ICU stay), dialysis
(day 1e3 of ICU stay), major surgery (day
e7 to 0 of ICU stay), pancreatitis (day e7
to 0 of ICU stay), steroids (day e7 to 3 of
ICU stay), other immunosuppressive agents
(day e7 to 0 of ICU stay) plus presence of
Candida spp. in any clinical specimen
Captured 66% of IC
Sensitivity ¼ 66%
Specificity ¼ 87%
PPV ¼ 9%
NPV ¼ 99%
Charles et al.55 136 ICU patients without bacterial
infection staying7 days in 36 mixed
ICUs [20 (15%) developed IC]
Candida score 3 points at day 7 [sum of:
severe sepsis (2 points), surgery (1), total
parenteral nutrition (1), multifocal
candida colonization (1)] plus
procalcitonin 0.3 ng/mL
Captured 80% of IC
Sensitivity ¼ 80%
Specificity ¼ 74%
PPV ¼ 59%
NPV ¼ 89%
Ostrosky-Zeichner et al.56 597 ICU patients [22 (4%) with proven
or probable IC] staying 4 days in six
US ICUs
Predictive rule: all of: mechanical
ventilation, broad-spectrum antibiotics
and central venous catheter (day 1e3 of
ICU stay); plus one of: total parenteral
nutrition (day 1e3 of ICU stay), dialysis
(day 1e3 of ICU stay), major surgery (day
e7 to 0 of ICU stay), pancreatitis (day e7
to 0 of ICU stay), steroids (day e7 to 3),
other immunosuppressive agents (day e7
to 0 of ICU stay)
Captured 90% of IC
Sensitivity ¼ 90%
Specificity ¼ 48%
PPV ¼ 6%
NPV ¼ 99%
Hermsen et al.57 Matched case of IC (88) vs control
(352) study
Predictive rule (Nebraska Medical Center
rule) all of: broad-spectrum antibiotics
and central venous catheter and total
parenteral nutrition and steroids and
abdominal surgery (day 1e3 of ICU stay)
Captured 85% of IC
Sensitivity ¼ 84%
Specificity ¼ 60%
PPV ¼ 5%
NPV ¼ 99%
IC, invasive candidiasis; ICU, intensive care unit; PPV, positive predictive value; NPV, negative predictive value.
a Adapted from Eggimann and Ostrosky-Zeichner.21
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placebo and 9.8% (10/102) in patients receiving caspofungin
(P ¼ 0.14). Treatment safety, length of stay, antifungal use,
and mortality did not differ between groups. The authors
concluded that caspofungin prophylaxis was safe, with a non-
significant tendency to reduce invasive candidiasis. Two
currently unpublished studies demonstrated no clinical use-
fulness of predictive rules based on clinical factors in guiding
empirical antifungal treatment. The first, entitled ‘Pilot
feasibility study with patients who are at high risk for devel-
oping invasive candidiasis in a critical care setting’
(ClinicalTrials.gov identifier: NCT01045798), was terminated
due to a low recruitment rate after the inclusion of only 15
patients. The second study, entitled ‘An exploratory study to
compare the efficacy and safety of micafungin as a pre-
emptive treatment of invasive candidiasis versus placebo in
high risk surgical subjects e a multicentre, randomized,
double-blind study’ (ClinicalTrials.gov identifier:
NCT01122368), included only surgical critically ill patients.
Preliminary results showed a high proportion of invasive
candidiasis cases at study entry. The overall rate of infection
did not differ between patients receiving pre-emptive anti-
fungal treatment (11.1%) and those receiving placebo (8.9%),
but the number of patients excluded from the analysis resulted
in insufficient statistical power.61
These three studies strongly suggest that despite better
positive predictive value than colonization index and candida
score, predictive rules may not be feasible at the bedside.Antifungal 
Surg
Colonization index (CI)
High risk of invasive candidiasis
CI ≥ 0.5 or CS ≥ 3
Consider
empiric antifungal treatment
No. of sites/no. of sites screened
2x weekly
No
Risk assessment evaluation
Figure 1. Risk assessment strategThe clinical paradox arising from the use of risk-based
strategies
The laborious nature of the clinical use and the limited
availability of solid clinical data explain the low level of evi-
dence attributed by experts to these risk-based strategies in
consensus guidelines. Nevertheless, they are widely used at
bedside and have succeeded in decreasing the incidence of
invasive candidiasis.14,17,18,25,62 This picture reflects opposing
strategies: clinicians concerned by the worse prognosis of
delayed treatment start antifungals early, even in low-risk
patients; whereas experts, more concerned by the negative
ecological impact and cost of antifungals, recommend delayed
prescription, which risks failing to identify patients requiring
early treatment.
New insight into risk-based strategies
We have emphasized that these diagnostic risk-based strat-
egies result in the following paradigm: the most sensitive
method (colonization index) increases the number of patients
receiving useless treatment, whereas the most specific method
(predictive rules) increases the number of patients not
receiving early antifungals and developing invasive candidi-
asis.7,21,23 Objective analysis of the accuracy of the risk-based
strategies shows that the NPVs of these strategies are much
higher than their PPVs, for which they were developed
(Table II).30,5154,56 Among them, only the NPV of the candidatreatment in critically ill patients ?
ical patient at very high risk
Candida score (CS)
CI < 0.5 or CS < 3
Avoid
empiric antifungal treatment
Low risk of invasive candidiasis
Antifungal prophylaxis
-Anastomotic leakage
-Reopening of the digestive tract
-Surgery on ICU admission (1pt)
-Total parenteral nutrition (1pt)
-Severe sepsis (2pts)
-Candida colonization (1pt)
Yes
ies for antifungal treatment.
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trial.55
A practical approach for antifungal treatment in
critically ill patients
In patients perceived to be at risk of invasive candidiasis, we
propose to evaluate the appropriateness of early empirical
antifungal treatment by using both the PPVs and NPVs of the
risk assessment strategies (Figure 1). We suggest restricting
antifungal prophylaxis to surgical patients presenting with
anastomotic leakage after abdominal surgery or reopening of
the digestive tract during the same hospitalization to prevent
the development of invasive candidiasis.18,38,39 For patients in
whom invasive candidiasis is suspected, early empirical anti-
fungal treatment should be considered when the candida score
is  3. In these cases, a colonization index calculated using the
available microbiological data of 0.5 strengthens the evi-
dence of a very high risk of invasive candidiasis. Early empirical
antifungal treatment should not be started in patients identi-
fied to be at low risk by a candida score <3. In these situations,
a colonization index calculated using the available microbio-
logical data of<0.5 strengthens the case for avoiding empirical
antifungal treatment; further exposure or additional risk fac-
tors are required for the development of invasive candidiasis,
and these will be captured by an increase in candida score or
colonization index.
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